Technical Analysis for ADXS - Advaxis, Inc.

Grade Last Price % Change Price Change
grade C 0.48 -2.44% -0.01
ADXS closed down 2.44 percent on Friday, March 22, 2019, on 1.62 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ADXS trend table...

Date Alert Name Type % Chg
Mar 22 Bearish Engulfing Bearish 0.00%
Mar 22 Calm After Storm Range Contraction 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 Calm After Storm Range Contraction -2.44%
Mar 21 Narrow Range Bar Range Contraction -2.44%
Mar 21 Wide Bands Range Expansion -2.44%
Mar 21 Up 3 Days in a Row Strength -2.44%
Mar 20 Calm After Storm Range Contraction 0.00%
Mar 20 Narrow Range Bar Range Contraction 0.00%
Mar 20 NR7 Range Contraction 0.00%

Older signals for ADXS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company's platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The company's products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey.
Medicine Biotechnology Cancer Infectious Diseases Cancers Prostate Cancer Tumor Immunotherapies Platform Technology Infectious Causes Of Cancer Head And Neck Cancer Cancer Vaccine Human Papillomavirus Infection Osteosarcoma Cervical Cancer Anal Cancer
Is ADXS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.04
52 Week Low 0.18
Average Volume 1,267,103
200-Day Moving Average 0.8269
50-Day Moving Average 0.3787
20-Day Moving Average 0.3988
10-Day Moving Average 0.4447
Average True Range 0.0559
ADX 34.34
+DI 38.68
-DI 15.0422
Chandelier Exit (Long, 3 ATRs ) 0.5123
Chandelier Exit (Short, 3 ATRs ) 0.4877
Upper Bollinger Band 0.5157
Lower Bollinger Band 0.2819
Percent B (%b) 0.85
BandWidth 58.625878
MACD Line 0.0295
MACD Signal Line 0.0182
MACD Histogram 0.0113
Fundamentals Value
Market Cap 19.71 Million
Num Shares 41.1 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.21
Price-to-Sales 9.06
Price-to-Book 1.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.57
Resistance 3 (R3) 0.57 0.53 0.56
Resistance 2 (R2) 0.53 0.51 0.54 0.55
Resistance 1 (R1) 0.51 0.50 0.49 0.51 0.54
Pivot Point 0.47 0.47 0.47 0.48 0.47
Support 1 (S1) 0.45 0.45 0.43 0.45 0.42
Support 2 (S2) 0.41 0.44 0.42 0.41
Support 3 (S3) 0.39 0.41 0.41
Support 4 (S4) 0.39